Vexim brings in financial expertise in-house for expansion
This article was originally published in Clinica
Executive Summary
French spinal technology firm Vexim has appointed Jérôme Marzinski deputy CEO. Mr Marzinski has a solid background in finance and within medtech; he has worked for vascular implants firm ev3, where he joined as international finance manager and was then promoted to European general manager. Following the acquisition of ev3 by Covidien and prior to joining Vexim, Mr Marzinski worked as a medtech consultant. He will report to the CEO of Vexim, Vincent Gardès. The Toulouse-based company is ramping up European commercialization of its SpineJack minimally invasive device for treating vertebral compression fractures.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.